Biodesix Announces Fourth Quarter and Year End 2021 Results

Fourth Quarter and Fiscal Year 2021 Lung Diagnostic Revenue of $5.4 Million and $18.7 Million Increased 48% and 49% over the comparable 2020 periods, respectively

Full-Scale Launch of GeneStrat... | March 14, 2022

Related Keywords

, Scott Hutton , Biopharma Services , Biodesix Inc , Genscript Inc , Oracle , Nasdaq , Full Year , Pharma Services , Common Stock Purchase Agreement , Nodify Lung , Diagnostic Cortex , Artificial Intelligence , Neutralization Test Kit , Private Securities Litigation Reform Act , Risk Factors , Balance Sheets , Biodesix , Nc Stock Exchange , News , Information , Press Release , Fourth , Quarter , End , Iscal , Ear , 021 , Young , Iagnostic , Revenue , F , Billion , Ncreased , Dover , The , Comparable , 020 , Launch , F Bdsx Us09075x1081 ,